Alison DeBlois - Nova Leap VP Operations
| NLH Stock | CAD 0.28 0.01 3.45% |
Insider
Alison DeBlois is VP Operations of Nova Leap Health
| Address | 7071 Bayers Road, Halifax, NS, Canada, B3L 2C2 |
| Phone | 902 401 9480 |
| Web | https://novaleaphealth.com |
Nova Leap Management Efficiency
The company has return on total asset (ROA) of 0.0279 % which means that it generated a profit of $0.0279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0249) %, meaning that it generated substantial loss on money invested by shareholders. Nova Leap's management efficiency ratios could be used to measure how well Nova Leap manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to 0.02 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (0.17). At this time, Nova Leap's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to climb to about 1.9 M in 2025, whereas Intangible Assets are likely to drop slightly above 909.5 K in 2025.Similar Executives
| Found 8 records | INSIDER Age | ||
| Christopher Panczuk | Bewhere Holdings | N/A | |
| Joyce MD | Reliq Health Technologies | N/A | |
| Lisa PEng | Reliq Health Technologies | N/A | |
| Joseph MBA | NeuPath Health | 56 | |
| Michael CFA | Reliq Health Technologies | N/A | |
| Dave McKay | Reliq Health Technologies | N/A | |
| Margaux Berry | Bewhere Holdings | N/A | |
| Chris Ryan | Reliq Health Technologies | N/A | |
Management Performance
| Return On Equity | -0.0249 | ||||
| Return On Asset | 0.0279 |
Nova Leap Health Leadership Team
Elected by the shareholders, the Nova Leap's board of directors comprises two types of representatives: Nova Leap inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nova. The board's role is to monitor Nova Leap's management team and ensure that shareholders' interests are well served. Nova Leap's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nova Leap's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chris LeBlanc, Company CFO | ||
| Alison DeBlois, VP Operations | ||
| Michael Gremley, Mang Devel | ||
| Melissa Anderson, Vice Operations |
Nova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nova Leap a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0249 | ||||
| Return On Asset | 0.0279 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 24.75 M | ||||
| Shares Outstanding | 86.21 M | ||||
| Shares Owned By Insiders | 40.76 % | ||||
| Number Of Shares Shorted | 12.7 K | ||||
| Price To Book | 0.94 X | ||||
| Price To Sales | 0.92 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nova Stock Analysis
When running Nova Leap's price analysis, check to measure Nova Leap's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Leap is operating at the current time. Most of Nova Leap's value examination focuses on studying past and present price action to predict the probability of Nova Leap's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Leap's price. Additionally, you may evaluate how the addition of Nova Leap to your portfolios can decrease your overall portfolio volatility.